The US could up­end bio­phar­ma man­u­fac­tur­ing. WuXi ri­vals have an open­ing

In Con­gress, in­flu­en­tial law­mak­ers see a Chi­nese gov­ern­ment threat to the US biotech sec­tor. In the com­pet­i­tive world of bio­phar­ma man­u­fac­tur­ing, com­pa­nies see an op­por­tu­ni­ty.

Over the past sev­er­al months, as WuXi AppTec, WuXi Bi­o­log­ics and BGI Group have been tar­get­ed by law­mak­ers with pro­posed leg­is­la­tion and sanc­tions, their ri­vals have qui­et­ly — and not so qui­et­ly — used the mo­ment to try and gain mar­ket share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER